Perception and practice of sublingual immunotherapy among practicing allergists. (Q46015098)

18 December 2017

title

Perception and practice of sublingual immunotherapy among practicing allergists. (English)

1 reference

18 December 2017

1 reference

Mark H Tucker

1

1 reference

18 December 2017

Michael S Tankersley

series ordinal

2

1 reference

18 December 2017

ACAAI Immunotherapy and Diagnostics Committee

series ordinal

3

1 reference

18 December 2017

publication date

1 October 2008

1 reference

18 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

18 December 2017

volume

101

1 reference

18 December 2017

issue

4

1 reference

18 December 2017

page(s)

419-425

1 reference

18 December 2017

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Sublingual immunotherapy: a comprehensive review.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

1 reference

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Determinants of patient compliance with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Factors affecting compliance with allergen immunotherapy at a military medical center

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Patient dropouts before completion of optimal dose, multiple allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Children's compliance with allergen immunotherapy according to administration routes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Quantitative assessment of the adherence to sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Noninjection routes for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Anaphylaxis to sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Anaphylaxis to multiple pollen allergen sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Anaphylaxis by latex sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Safety of sublingual immunotherapy in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Dose adjustment practices among allergists for local reactions to immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Allergen immunotherapy: a practice parameter second update

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Sublingual immunotherapy and subcutaneous immunotherapy: issues in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Systemic reactions and fatalities associated with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

Evaluation of near-fatal reactions to allergen immunotherapy injections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960320-1

7 January 2021

10.1016/S1081-1206(10)60320-1

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017